Politics / Law

PPH – Avoiding potholes on the Patent Prosecution Highway

06.03.2012

A For years, the world’s major patent offices – including the EPO, USPTO and JPO – have been collaborating in the Patent Prosecution Highway (PPH) programme. Under the PPH, an applicant whose claims have been allowed in one participating patent office (Office 1) may pursue those claims in another participating patent office (Office 2). Under the PPH, Office 2 examines the claims in an accelerated manner, and may rely on the examination results of Office 1. The stated purpose of the PPH is to reduce work in examination and improve overall patent quality. An admissible request for examination under the PPH in Office 2 includes filing copies of the allowed claims and examination reports in Office 1. Translations of these documents may also be necessary.
At first, the PPH sounds like a great idea. Have one patent office search and examine claims for allowance, and then transfer this allowance to other participating PPH offices, allowing significant savings in both time and cost.
However, it is a common misconception that the PPH guarantees allowance of claims in Office 2 based solely on a previous allowance in Office 1. In fact, claims allowed in Office 1 do not automatically become allowable in Office 2 by requesting examination under the PPH. Office 2 may (but need not) rely on the examination results of Office 1. For instance, the EPO as Office 2 will often perform its own independent search and examination on a PPH application, even when the claims have already been allowed in another PPH-participating office. This situation can lead to unpleasant surprises.
For example, the claims allowed in Office 1 will often have been significantly restricted there to gain allowance. Following allowance in Office 1, the claims then enter Office 2 under the PPH in this restricted form. In an independent search, Office 2 (e.g. EPO) may identify prior not cited in Office 1, or may interpret aleady cited prior art differently than Office 1. In such a case, it may be impossible to obtain allowance in Office 2 for the claims already allowed in Office 1. However, since Office 2 has already searched restricted claims, it may also be impossible to shift to other allowable subject matter, because claims may only be amended within the bounds of what was searched. In such cases, the applicant may need to file costly divisional applications to pursue other claims.
Applicants are therefore advised not to view the PPH as a means of circumventing the patentability requirements of one office by relying on allowance in another. Subject matter not allowable in Office 2 does not become allowable there simply by participation in the PPH.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/pph-avoiding-potholes-on-the-patent-prosecution-highway.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR30.9%
  • CO.DON3.13 EUR26.2%
  • FORMYCON8.03 EUR17.7%

FLOP

  • CYTOS0.19 CHF-24.0%
  • ADDEX3.13 CHF-21.4%
  • EVOTEC3.06 EUR-18.2%

TOP

  • SANTHERA88.65 CHF2088.9%
  • PAION3.18 EUR238.3%
  • CO.DON3.13 EUR229.5%

FLOP

  • CYTOS0.19 CHF-95.1%
  • 4SC1.06 EUR-45.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 29.09.2014


Current issue

All issues

Product of the week

Products